Abstract

Cyclic adenosine monophosphate (cAMP) is a master regulator of mitochondrial metabolism but its precise mechanism of action yet remains unclear. Here, we found that a dietary saturated fatty acid (FA), palmitate increased intracellular cAMP synthesis through the palmitoylation of soluble adenylyl cyclase in cardiomyocytes. cAMP further induced exchange protein directly activated by cyclic AMP 1 (Epac1) activation, which was upregulated in the myocardium of obese patients. Epac1 enhanced the activity of a key enzyme regulating mitochondrial FA uptake, carnitine palmitoyltransferase 1. Consistently, pharmacological or genetic Epac1 inhibition prevented lipid overload, increased FA oxidation (FAO), and protected against mitochondrial dysfunction in cardiomyocytes. In addition, analysis of Epac1 phosphoproteome led us to identify two key mitochondrial enzymes of the the β-oxidation cycle as targets of Epac1, the long-chain FA acyl-CoA dehydrogenase (ACADL) and the 3-ketoacyl-CoA thiolase (3-KAT). Epac1 formed molecular complexes with the Ca2+/calmodulin-dependent protein kinase II (CaMKII), which phosphorylated ACADL and 3-KAT at specific amino acid residues to decrease lipid oxidation. The Epac1-CaMKII axis also interacted with the α subunit of ATP synthase, thereby further impairing mitochondrial energetics. Altogether, these findings indicate that Epac1 disrupts the balance between mitochondrial FA uptake and oxidation leading to lipid accumulation and mitochondrial dysfunction, and ultimately cardiomyocyte death.

Details

Title
Cyclic AMP-binding protein Epac1 acts as a metabolic sensor to promote cardiomyocyte lipotoxicity
Author
Laudette Marion 1 ; Sainte-Marie Yannis 2 ; Cousin Grégoire 3 ; Bergonnier Dorian 2 ; Ismahane, Belhabib 2 ; Brun Stéphanie 3 ; Formoso Karina 2 ; Laib Loubna 2 ; Tortosa Florence 2 ; Bergoglio Camille 2 ; Marcheix Bertrand 3 ; Borén, Jan 4 ; Lairez Olivier 3   VIAFID ORCID Logo  ; Fauconnier Jérémy 5 ; Lucas, Alexandre 2 ; Mialet-Perez, Jeanne 2   VIAFID ORCID Logo  ; Moro Cédric 2 ; Lezoualc’h Frank 2   VIAFID ORCID Logo 

 Université Paul Sabatier, UMR 1297-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X); University of Gothenburg and Sahlgrenska University Hospital, Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582) 
 Université Paul Sabatier, UMR 1297-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X) 
 Université Paul Sabatier, UMR 1297-I2MC, Institut des Maladies Métaboliques et Cardiovasculaires, Inserm, Toulouse, France (GRID:grid.15781.3a) (ISNI:0000 0001 0723 035X); Centre Hospitalier Universitaire de Toulouse Rangueil, Toulouse, France (GRID:grid.411175.7) (ISNI:0000 0001 1457 2980) 
 University of Gothenburg and Sahlgrenska University Hospital, Department of Molecular and Clinical Medicine, Wallenberg Laboratory, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582) 
 PHYMEDEXP, Université de Montpellier, CNRS, INSERM, CHRU Montpellier, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X) 
Publication year
2021
Publication date
Sep 2021
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2568105971
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.